Nisa Investment Advisors LLC Sells 2,845 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Nisa Investment Advisors LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,049 shares of the company’s stock after selling 2,845 shares during the period. Nisa Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $16,558,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Benjamin F. Edwards & Company Inc. boosted its position in IDEXX Laboratories by 2.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,657 shares of the company’s stock valued at $807,000 after buying an additional 45 shares during the period. Frank Rimerman Advisors LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $253,000. Public Sector Pension Investment Board boosted its holdings in shares of IDEXX Laboratories by 67.6% in the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock valued at $1,500,000 after purchasing an additional 1,241 shares during the period. Marshall Wace LLP grew its stake in IDEXX Laboratories by 2.5% in the second quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock worth $9,988,000 after purchasing an additional 500 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in IDEXX Laboratories by 60.5% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 15,914 shares of the company’s stock worth $7,753,000 after purchasing an additional 5,998 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Trading Up 0.8 %

NASDAQ:IDXX opened at $430.59 on Thursday. The stock has a market capitalization of $35.26 billion, a price-to-earnings ratio of 41.52, a PEG ratio of 3.53 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $423.26 and a 200 day moving average of $457.04.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the prior year, the business posted $2.53 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IDXX shares. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.